Overview

The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:
0

Participant gender:
All

Summary

The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome patients. To analyze the number and timing of recurrence based on a long-term follow-up.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Hyaluronic Acid

Criteria

Inclusion Criteria:

1. Male and female aged 20 yrs or greater

2. Patients diagnosed with Hunner lesion in IC(interstitial cystitis)/BPS(Bladder Pain
Syndrome) and who is scheduled to undergo transurethral resection

3. Symptom persisted more than 6 months

4. Pain VAS ≥4

Exclusion Criteria:

1. History of augmentation cystoplasty or previous transurethral coagulation/resection
due to IC/BPS

2. Child-bearing potential, pregnant or nursing women.

3. Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.

4. Urinary tract infection during run-in periods.

5. Genitourinary tuberculosis or bladder,urethral and prostate cancer

6. Recurrent urinary tract infection

7. History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal
delivery or Cesarean section,prostate operation or treatment etc within 6months.

8. Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism
etc.-

9. Using a indwelling catheter or execution of intermittent self catheterization